LabGenius combines artificial intelligence, robotic automation and synthetic biology to evolve next-generation protein therapeutics.

LabGenius develops therapeutics of high value for diseases of unmet need. The company deploys machine intelligence to model the relationship between DNA sequence and protein function, while improving the predictive accuracy of these models through experimental lab data generated through its smart robotic platform.
-
Industry
-
Milestones
- Lux investment: 2019
-
Founders
- James Field
LUX Partners
-
Latest Tweets
- We’re thrilled to announce that we’ve raised a further $15M in a round, led by @atomico (@irinahaivas) and supporte… https://t.co/dHDO0sOTeO
- State of AI Report 2020 is here!💥💥💥 Check out Data Scientist Katya @ktptnts talking about our contribution. Read th… https://t.co/jmNgq0rdIu